Short answer · Medically reviewed summary · Last updated: 2023-07-13
Kasabach-Merritt syndrome (KMS) is a rare condition characterized by the combination of a vascular tumor, known as a hemangioma, and a consumptive coagulopathy. The prevalence of KMS is difficult to determine precisely due to its rarity and the lack of comprehensive data.
What is the prevalence of Kasabach-Merritt syndrome?
Prevalence of Kasabach-Merritt syndrome: how many people are affected worldwide, differences by sex and region, with sources.
Kasabach-Merritt syndrome (KMS) is a rare condition characterized by the combination of a vascular tumor, known as a hemangioma, and a consumptive coagulopathy. The prevalence of KMS is difficult to determine precisely due to its rarity and the lack of comprehensive data. However, it is estimated to occur in approximately 1 in 200,000 to 1 in 500,000 live births.
KMS predominantly affects infants and young children, with most cases being diagnosed within the first year of life. It can occur in both males and females, and there is no known ethnic or geographic predisposition.
The exact cause of KMS is still not fully understood, but it is believed to result from an abnormal growth of blood vessels within the hemangioma, leading to platelet trapping and consumption, ultimately causing a severe decrease in platelet count and clotting factors.
Early diagnosis and prompt treatment are crucial to prevent life-threatening bleeding complications associated with KMS. Treatment options may include pharmacological interventions, embolization, surgical resection of the hemangioma, or a combination of these approaches.
In conclusion, while Kasabach-Merritt syndrome is a rare condition, its impact on affected individuals can be severe. Further research and awareness are needed to better understand and manage this complex disorder.
